Table 2 VEN combined with epigenetic, antibody or targeted drugs for R/R AML

Regimen

VEN + ASTX727

VEN + AZA + chidamide

VEN + AZA + HHT

VEN + AZA + HHT + sorafenib

VEN + enasidenib

VEN + PegC

Study type

Phase II

Phase II

Retro

Phase II

Phase Ib/II

Phase I

NCT number

NCT04746235

N/A

N/A

N/A

NCT04092179

NCT04666649

Study period

N/A

2022–2023

2018–2022

2020–2022

2020–2022

N/A

Patients number

10

53

172

51

23

26

Male

N/A

31 (58.5%)

N/A

N/A

16 (59.3%)

10 (38.5%)

Age range (years)

46–75

18–73

N/A

31–57

23–84

24–79

Median prior lines of therapies

2 (1–4)

N/A

N/A

N/A

1 (1–2)

2 (1–5)

Prior exposure to VEN

N/A

N/A

N/A

N/A

N/A

18 (69.2%)

Response rate

ORR 50%, CR/CRi 50%

ORR 68%, CRc 53%

CRc 66.3%

ORR 82.4%, CRc 76.5%

ORR 70%, CR 57%

ORR 47%

Grade ≥ 3 AEs

Neutropenic fever 23%

No

N/A

Neutropenia 92.2%

febrile neutropenia 41%

N/A

Follow-up (months)

12.8

6.7

N/A

10.3

17.1

N/A

Survival

Median OS 7.6 months, median RFS or DOR 4.6 months

Median EFS 6 months, Median OS not reached

Median OS not reached

Median OS 18.1 months, EFS 13.2 months

Median OS 9.4 months, the 2-year OS rate 42%

N/A